Rakuten Securities Inc. Makes New $1.37 Million Investment in Pfizer Inc. (NYSE:PFE)

Rakuten Securities Inc. purchased a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 47,586 shares of the biopharmaceutical company’s stock, valued at approximately $1,370,000. Pfizer makes up approximately 1.1% of Rakuten Securities Inc.’s holdings, making the stock its 18th largest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. RB Capital Management LLC boosted its stake in shares of Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. boosted its stake in shares of Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares in the last quarter. United Bank boosted its stake in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC boosted its position in Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp boosted its position in Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.8 %

PFE stock traded down $0.22 during trading on Wednesday, hitting $25.69. 28,885,313 shares of the stock traded hands, compared to its average volume of 33,467,946. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.33. The firm’s 50 day moving average is $27.23 and its two-hundred day moving average is $28.79. The stock has a market cap of $145.47 billion, a price-to-earnings ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PFE shares. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.